

Medical Policy Update

We develop and revise medical policies in response to changing medical technology. Benefit determinations are made based on the medical policy in effect at the time of the provision of services. Please review the following medical policies, all of which can be found on our Blue Advantage Resource Page at www.lablue.com/providers, click “Go to BA Resources” at the bottom of the screen, and then the “New/Revised Medicare Advantage Medical Policies” tab.

New Medical Policies

Effective Oct. 1, 2025

<u>Policy No.</u>	<u>Policy Name</u>
124	Proton Beam Therapy
125	Radioembolization of Primary and Metastatic Tumors of the Liver
126	Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors
127	Radiofrequency Ablation of Primary or Metastatic Liver Tumors
128	eptinezumab-jjmr (Vyepti™)
129	cantharidin (Ycanth™)
130	foscarbidopa/foslevodopa injection (Vyalev™)

Effective Nov. 1, 2025

131	Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas or Bone
133	ADAMTS13, recombinant-krhn (Adzynma™)
134	evinacumab-dgnb (Evkeeza™)
136	axatilimab-csfr (Niktimvo™)
137	fitusiran (Qfitlia™)
138	Therapeutic Radiopharmaceuticals in Oncology

Revised Medical Policies

Effective Sept. 1, 2025

<u>Policy No.</u>	<u>Policy Name</u>
120	Category III CPT Codes*

**Coding changes were made to this policy that are effective Sept. 1, 2025.*